// App-Quantinova.ai

TPS5091 : A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.

Researchers

Presenter

  • Michael J. Morris

Principal Investigators

  • Ronald De Wit

  • Nicholas J. Vogelzang

  • Scott T. Tagawa

  • Celestia S. Higano

  • Paul Hamberg

Medical Centers

  • Memorial Sloan Kettering Cancer Center, New York, NY, Erasmus MC Cancer Institute, Rotterdam, Netherlands

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV, Weill Cornell Medicine, New York, NY, Fred Hutchinson Cancer Research Center, Seattle, WA, Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Radium-223 Dichloride

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT03574571

Sponsors

  • Memorial Sloan Kettering Cancer Center

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved